vs
FORMFACTOR INC（FORM）とPacira BioSciences, Inc.（PCRX）の財務データ比較。上の社名をクリックして会社を切り替えられます
FORMFACTOR INCの直近四半期売上が大きい（$215.2M vs $196.9M、Pacira BioSciences, Inc.の約1.1倍）。FORMFACTOR INCの前年同期比売上増加率が高い（13.6% vs 5.1%）。Pacira BioSciences, Inc.の直近四半期フリーキャッシュフローが多い（$43.5M vs $34.7M）。過去8四半期でFORMFACTOR INCの売上複合成長率が高い（12.9% vs 8.5%）
FormFactor, Inc.は米国カリフォルニア州リバモアに本社を置く集積回路向け試験・測定技術のサプライヤーで、半導体企業向けにデバイス性能を向上させる製品を提供し、各種試験測定ソリューションを展開しています。
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
FORM vs PCRX — 直接比較
売上が大きい
FORM
1.1倍大きい
$196.9M
売上成長率が高い
FORM
+8.4%の差
5.1%
フリーキャッシュフローが多い
PCRX
FCF $8.8M多い
$34.7M
2年売上CAGRが高い
FORM
2年複合成長率
8.5%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $215.2M | $196.9M |
| 純利益 | $23.2M | — |
| 粗利率 | 42.2% | 79.5% |
| 営業利益率 | 10.9% | 1.2% |
| 純利益率 | 10.8% | — |
| 売上前年比 | 13.6% | 5.1% |
| 純利益前年比 | 139.2% | — |
| EPS（希薄化後） | $0.29 | $0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上FORMPCRX
| Q4 25 | $215.2M | $196.9M | ||
| Q3 25 | $202.7M | $179.5M | ||
| Q2 25 | $195.8M | $181.1M | ||
| Q1 25 | $171.4M | $168.9M | ||
| Q4 24 | $189.5M | $187.3M | ||
| Q3 24 | $207.9M | $168.6M | ||
| Q2 24 | $197.5M | $178.0M | ||
| Q1 24 | $168.7M | $167.1M |
純利益FORMPCRX
| Q4 25 | $23.2M | — | ||
| Q3 25 | $15.7M | $5.4M | ||
| Q2 25 | $9.1M | $-4.8M | ||
| Q1 25 | $6.4M | $4.8M | ||
| Q4 24 | $9.7M | — | ||
| Q3 24 | $18.7M | $-143.5M | ||
| Q2 24 | $19.4M | $18.9M | ||
| Q1 24 | $21.8M | $9.0M |
粗利率FORMPCRX
| Q4 25 | 42.2% | 79.5% | ||
| Q3 25 | 39.8% | 80.9% | ||
| Q2 25 | 37.3% | 77.4% | ||
| Q1 25 | 37.7% | 79.7% | ||
| Q4 24 | 38.8% | 78.7% | ||
| Q3 24 | 40.7% | 76.9% | ||
| Q2 24 | 44.0% | 75.1% | ||
| Q1 24 | 37.2% | 71.6% |
営業利益率FORMPCRX
| Q4 25 | 10.9% | 1.2% | ||
| Q3 25 | 8.9% | 3.5% | ||
| Q2 25 | 6.3% | 4.7% | ||
| Q1 25 | 1.9% | 1.2% | ||
| Q4 24 | 4.1% | 13.2% | ||
| Q3 24 | 8.6% | -82.8% | ||
| Q2 24 | 9.0% | 15.9% | ||
| Q1 24 | 12.6% | 7.9% |
純利益率FORMPCRX
| Q4 25 | 10.8% | — | ||
| Q3 25 | 7.7% | 3.0% | ||
| Q2 25 | 4.6% | -2.7% | ||
| Q1 25 | 3.7% | 2.8% | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 9.0% | -85.1% | ||
| Q2 24 | 9.8% | 10.6% | ||
| Q1 24 | 12.9% | 5.4% |
EPS（希薄化後）FORMPCRX
| Q4 25 | $0.29 | $0.05 | ||
| Q3 25 | $0.20 | $0.12 | ||
| Q2 25 | $0.12 | $-0.11 | ||
| Q1 25 | $0.08 | $0.10 | ||
| Q4 24 | $0.12 | $0.38 | ||
| Q3 24 | $0.24 | $-3.11 | ||
| Q2 24 | $0.25 | $0.39 | ||
| Q1 24 | $0.28 | $0.19 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $103.3M | $238.4M |
| 総負債低いほど良い | $12.2M | $372.2M |
| 株主資本純資産 | $1.0B | $693.1M |
| 総資産 | $1.2B | $1.3B |
| 負債/資本比率低いほどレバレッジが低い | 0.01× | 0.54× |
8四半期トレンド — 暦四半期で整列
現金・短期投資FORMPCRX
| Q4 25 | $103.3M | $238.4M | ||
| Q3 25 | $266.0M | $246.3M | ||
| Q2 25 | $249.3M | $445.9M | ||
| Q1 25 | $299.0M | $493.6M | ||
| Q4 24 | $360.0M | $484.6M | ||
| Q3 24 | $354.5M | $453.8M | ||
| Q2 24 | $357.6M | $404.2M | ||
| Q1 24 | $349.2M | $325.9M |
総負債FORMPCRX
| Q4 25 | $12.2M | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $13.3M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
株主資本FORMPCRX
| Q4 25 | $1.0B | $693.1M | ||
| Q3 25 | $1.0B | $727.2M | ||
| Q2 25 | $990.0M | $757.8M | ||
| Q1 25 | $965.9M | $798.5M | ||
| Q4 24 | $947.8M | $778.3M | ||
| Q3 24 | $955.0M | $749.6M | ||
| Q2 24 | $947.9M | $879.3M | ||
| Q1 24 | $923.8M | $892.2M |
総資産FORMPCRX
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.2B | $1.6B | ||
| Q4 24 | $1.1B | $1.6B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $1.2B | $1.6B | ||
| Q1 24 | $1.1B | $1.6B |
負債/資本比率FORMPCRX
| Q4 25 | 0.01× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.01× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $46.0M | $43.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $34.7M | $43.5M |
| FCFマージンFCF / 売上 | 16.1% | 22.1% |
| 設備投資強度設備投資 / 売上 | 5.3% | 0.1% |
| キャッシュ転換率営業CF / 純利益 | 1.98× | — |
| 直近12ヶ月FCF直近4四半期 | $11.7M | $136.7M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローFORMPCRX
| Q4 25 | $46.0M | $43.7M | ||
| Q3 25 | $27.0M | $60.8M | ||
| Q2 25 | $18.9M | $12.0M | ||
| Q1 25 | $23.5M | $35.5M | ||
| Q4 24 | $35.9M | $33.1M | ||
| Q3 24 | $26.7M | $53.9M | ||
| Q2 24 | $21.9M | $53.2M | ||
| Q1 24 | $33.0M | $49.1M |
フリーキャッシュフローFORMPCRX
| Q4 25 | $34.7M | $43.5M | ||
| Q3 25 | $19.5M | $57.0M | ||
| Q2 25 | $-47.4M | $9.3M | ||
| Q1 25 | $5.0M | $26.9M | ||
| Q4 24 | $28.3M | $31.0M | ||
| Q3 24 | $17.8M | $49.8M | ||
| Q2 24 | $13.5M | $51.6M | ||
| Q1 24 | $19.6M | $46.3M |
FCFマージンFORMPCRX
| Q4 25 | 16.1% | 22.1% | ||
| Q3 25 | 9.6% | 31.7% | ||
| Q2 25 | -24.2% | 5.1% | ||
| Q1 25 | 2.9% | 15.9% | ||
| Q4 24 | 14.9% | 16.6% | ||
| Q3 24 | 8.6% | 29.6% | ||
| Q2 24 | 6.8% | 29.0% | ||
| Q1 24 | 11.6% | 27.7% |
設備投資強度FORMPCRX
| Q4 25 | 5.3% | 0.1% | ||
| Q3 25 | 3.7% | 2.2% | ||
| Q2 25 | 33.8% | 1.5% | ||
| Q1 25 | 10.8% | 5.1% | ||
| Q4 24 | 4.0% | 1.1% | ||
| Q3 24 | 4.3% | 2.4% | ||
| Q2 24 | 4.3% | 0.9% | ||
| Q1 24 | 8.0% | 1.7% |
キャッシュ転換率FORMPCRX
| Q4 25 | 1.98× | — | ||
| Q3 25 | 1.72× | 11.20× | ||
| Q2 25 | 2.08× | — | ||
| Q1 25 | 3.68× | 7.37× | ||
| Q4 24 | 3.70× | — | ||
| Q3 24 | 1.43× | — | ||
| Q2 24 | 1.13× | 2.82× | ||
| Q1 24 | 1.52× | 5.47× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
FORM
| Foundry Logic Product Group | $92.2M | 43% |
| DRAM Product Group | $73.3M | 34% |
| Systems Product Group | $42.3M | 20% |
| Flash Product Group | $7.4M | 3% |
| Transferred Over Time | $1.8M | 1% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
